Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
SonoVue + Focused Ultrasound + FOLFIRINOX
- Development stage
- Unknown
- Lead developer
- St. Olavs University Hospital
- Modality
- Drug Delivery Systems, Small Molecules
- Administration
- Intravenous
01
Overview
This therapeutic regimen, evaluated by St. Olavs Hospital, combines the FOLFIRINOX chemotherapy protocol (fluorouracil, leucovorin, irinotecan, and oxaliplatin) with focused ultrasound (FUS) and SonoVue microbubbles for the treatment of inoperable pancreatic ductal adenocarcinoma. The approach leverages ultrasound-mediated acoustic cavitation (sonoporation) to physically disrupt the dense tumor stroma and increase the permeability of the blood-tumor barrier. By temporarily enhancing the local uptake of cytotoxic agents, the treatment aims to overcome the chemoresistance and poor drug penetration typically associated with pancreatic tumors, potentially improving survival outcomes while minimizing systemic toxicity.
- Brand names
- SonoVue
- Other names
- chemotherapy-St. Olavs Hospital-pancreatic ductal adenocarcinomaUltrasound-enhanced chemotherapyFUS-enhanced FOLFIRINOX
02
Targets
TOP1 (DNA Topoisomerase I)TS (Thymidylate synthase)
Beyond the preview
Go deeper on SonoVue + Focused Ultrasound + FOLFIRINOX.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on SonoVue + Focused Ultrasound + FOLFIRINOX.